CYCN
Cyclerion Therapeutics Inc
$
1.380
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.380
Open
1.370
VWAP
1.37
Vol
11.67K
Mkt Cap
5.65M
Low
1.370
Amount
16.04K
EV/EBITDA(TTM)
--
Total Shares
2.50M
EV
1.08M
EV/OCF(TTM)
--
P/S(TTM)
1.44
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Show More
Valuation Metrics
The current forward P/E ratio for Cyclerion Therapeutics Inc (CYCN.O) is -0.04, compared to its 5-year average forward P/E of -0.84. For a more detailed relative valuation and DCF analysis to assess Cyclerion Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.84
Current PE
-0.04
Overvalued PE
0.27
Undervalued PE
-1.95
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.19
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.34
Undervalued EV/EBITDA
-0.72
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
9.30
Current PS
1.44
Overvalued PS
23.03
Undervalued PS
-4.44
Financials
Annual
Quarterly
FY2025Q3
YoY :
+351.03%
875.00K
Total Revenue
FY2025Q3
YoY :
-10.82%
-1.01M
Operating Profit
FY2025Q3
YoY :
+34.99%
-976.00K
Net Income after Tax
FY2025Q3
YoY :
+3.45%
-0.30
EPS - Diluted
FY2025Q3
N/A
Free Cash Flow
FY2025Q3
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q3
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q3
YoY :
-70.07%
-111.54
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CYCN News & Events
Events Timeline
2025-09-23 (ET)
2025-09-23
16:08:20
Cyclerion Signs Licensing Deal with MIT and Unveils Strategic Relaunch
2025-05-06 (ET)
2025-05-06
16:59:34
Cyclerion Therapeutics files to sell 500K shares of common stock for holders
2024-12-17 (ET)
2024-12-17
07:20:51
Cyclerion Therapeutics announces update on next stage of growth
Sign Up For More Events
Sign Up For More Events
News
6.0
11-10BenzingaCycurion Secures Over $1 Million Contract to Upgrade Federal Emergency Warning System
7.5
09-24NASDAQ.COMWhat’s Driving the Surge in Cyclerion Stock During Pre-market Trading?
9.0
09-24NASDAQ.COMBiotech Stocks Rise After Hours Following Trial News and Strategic Developments
Sign Up For More News
People Also Watch
OMH
Ohmyhome Ltd
1.170
USD
-1.52%
GMM
Global Mofy AI Ltd
1.660
USD
0.00%
LDWY
Lendway Inc
3.750
USD
0.00%
POAI
Predictive Oncology Inc
6.500
USD
0.00%
MGRX
Mangoceuticals Inc
1.250
USD
+5.04%
ALUR
Allurion Technologies Inc
1.370
USD
+3.01%
SLE
Super League Enterprise Inc
1.120
USD
-8.20%
FGI
FGI Industries Ltd
4.920
USD
-1.99%
ROMA
Roma Green Finance Ltd
2.720
USD
-0.73%
FAQ
What is Cyclerion Therapeutics Inc (CYCN) stock price today?
The current price of CYCN is 1.38 USD — it has decreased -4.17 % in the last trading day.
What is Cyclerion Therapeutics Inc (CYCN)'s business?
What is the price predicton of CYCN Stock?
What is Cyclerion Therapeutics Inc (CYCN)'s revenue for the last quarter?
What is Cyclerion Therapeutics Inc (CYCN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Cyclerion Therapeutics Inc (CYCN)'s fundamentals?
How many employees does Cyclerion Therapeutics Inc (CYCN). have?